EmVenio Research Expands Role as Global Impact Partner
![EmVenio Research Expands Role as Global Impact Partner](https://investorshangout.com/images/blog/ihnews-EmVenio%20Research%20Expands%20Role%20as%20Global%20Impact%20Partner.jpg)
EmVenio Research Joins SCRS as Global Impact Partner
EmVenio Research, a notable clinical research organization, has recently made a significant stride by becoming a part of the Society of Clinical Research Sites (SCRS) as a Global Impact Partner. This move emphasizes EmVenio's commitment to advancing the clinical research landscape.
Empowering Clinical Research
As a Global Impact Partner, EmVenio Research is set to collaborate with fellow research sites, sponsors, clinical organizations, and other professionals to innovate practices that enhance sustainability, patient engagement, and trial performance. The emphasis is on driving transformative solutions in the clinical trial arena.
Commitment to Accessibility
Thad Wolfman, President of EmVenio, stated, "EmVenio is committed to expanding awareness of the benefits of clinical research while also removing accessibility barriers for participants seeking potentially life-changing medical treatments." This partnership lays the groundwork for a collaborative approach toward improving the overall clinical research experience for participants.
Advancing Public Education
Every step taken by EmVenio aims to educate the public about the importance of clinical research and to increase participation, especially within underrepresented and diverse communities. Through their innovative network of mobile sites and adaptable methodologies, they strive to meet participants in their own communities, making participation easier and more accessible than ever before.
Leading the Way in Clinical Trials
EmVenio's extensive reach, developed through its partnership with PCM Trials, positions it as a major player in the clinical research landscape. Together, they operate what is regarded as the largest independent hybrid site network, offering a wealth of options for local clinical trial access globally. Their services include mobile sites, home visits, and virtual consultations, ensuring that trial participation is as convenient as possible.
Engagement at SCRS Global Site Solutions Summit
Since its inception in 2022, EmVenio has been an active participant in SCRS. They are set to engage with the research community during the SCRS Global Site Solutions Summit, showcasing their patient-centric model aimed at enhancing diversity in trials. They will also have a booth for attendees to explore their innovative approaches and success stories. Furthermore, Phillip Stanford, a senior leader at EmVenio, will be contributing to a panel discussion focused on the impact of technology on trial efficiency, sharing insights and experiences with industry colleagues.
Connecting with EmVenio
Those interested in learning more about EmVenio's initiatives and how they can enhance the clinical trial process can easily schedule time for a meeting during the SCRS event.
About EmVenio Research
EmVenio Research, part of PCM Trials, offers a robust network of clinical trial sites strategically positioned in underserved communities, focusing on engaging a diverse patient demographic. Through extensive collaboration with skilled clinicians and leading researchers, EmVenio delivers clinical research services that prioritize reducing participant burden. To learn more about their mission and offerings, visit emvenio.com.
Frequently Asked Questions
What is the significance of EmVenio joining SCRS?
This partnership with SCRS allows EmVenio to deepen its engagement in clinical research and enhance collaboration across the research landscape.
How does EmVenio improve clinical trial accessibility?
EmVenio focuses on providing mobile sites and home visit services to meet participants where they are, thus increasing trial accessibility.
What are the goals of EmVenio's partnership with SCRS?
The partnership aims to promote innovation, sustainability, and patient engagement within the clinical research community.
Who from EmVenio will be attending the SCRS Global Site Solutions Summit?
Members of EmVenio's leadership and research team, including senior director Phillip Stanford, will represent the organization at the event.
What services does EmVenio offer?
EmVenio provides a scalable network of trial sites, focusing on engaging diverse populations through various innovative engagement strategies.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
Related Articles
- Binswanger Welcomes Brooke Oldt as Senior VP of Corporate Services
- Cetera Welcomes Experienced Advisors to Wealth Partners Team
- Senior Insurance Solutions Partners with Integrity for Growth
- Oomnitza Welcomes Robert Potter as New Chief Executive Officer
- GlobalVetLink's Automation Tool Enhances Rabies Vaccine Management
- Ilegal Mezcal Launches Unique Reposado Caribbean Cask Finish
- Texas A&M Sports Properties Welcomes Azuna Partnership
- Myosin's Innovative Marketing Platform Redefines Advertising Impact
- Tower Arch Capital Partners with ACS Manufacturing for Growth
- Bybit Web3 Launches Babylon Season with Exciting Opportunities
- West Shore Home Appoints Al Patel as New Chief Marketing Officer
- Sumeet Chabria Joins Genesis as Senior Advisor for Growth
- Essential Gutter Maintenance Tips for Autumn Care This Season
- TrustGrid Partners with Department of Air Force for Innovation
- Chubb Welcomes Greg Giardiello as New Global Controller
- UBS Downgrades ASML Holdings Amid AI Hype Concerns
- Southeast Asia SME Software Market Forecast to Reach $12.9 Billion
- Spirit Blockchain Capital Deepens Alvara Protocol Partnership
- Evoke Pharma to Showcase Innovations in Investment Conference
- John Bonasera Joins Blue Matter, Enhancing Strategic Expertise
- Labatt Blue Light Unveils Exciting Promotions for Football Season
- Hilb Group Expands with Strategic Acquisition in Benefits Sector
- Zynex Announces Participation in Upcoming Global Investment Event
- Class Action Settlement for Packaged Tuna Purchasers Explained
- Cineverse Expands Data Security with LiveRamp Integration
Recent Articles
- Hackensack Meridian Health Foundation Gala Honors Eli Manning
- Goya Foods Launches GOYA® Cares Hydrate for Hope Campaign
- Peptide Therapeutics Market to Reach USD 85.9 Billion by 2031
- Southeast Asia SME Software Market Forecast to Reach $12.9 Billion
- Unlocking Love: CLR Brands' Fresh Ad Campaign on Cleaning
- Cyclacel Pharmaceuticals to Participate in Global Investment Conference
- Cadar Appoints Ralph Simons as CEO to Lead Fine Jewelry Brand
- Wearable Devices Innovates Gesture Control with Neural Tech
- SeaStar Medical Eliminates Long-Term Debt to Enhance Growth
- Fossil Group Welcomes Franco Fogliato as New CEO
- Understanding Nvidia's Stock Drops: Lessons for Investors
- Wakarusa Coach Partners with Model 1 for Vehicle Expansion
- EmVenio Research Expands Role as Global Impact Partner
- MARA Reports August Mining Updates and Bitcoin Production
- Eisai Showcases New Cancer Research Data at ESMO 2024
- Understanding Why Most Americans Avoid Investing in Stocks
- Koryx Copper Welcomes New Leadership to Accelerate Growth
- Bombardier Set to Showcase at September Conferences
- Anghami Achieves 18.3% Subscriber Growth Post-OSN+ Deal
- Cardano vs. Polkadot: Who Will Dominate Blockchain Governance?
- Hangcha Forklift Canada Launches Advanced Equipment Solutions
- Robertshaw Unveils 780U Series for Universal Ignition Solutions
- Jad Lahoud Named Partner and Board Director at eMerge Americas
- Caris Life Sciences to Present Groundbreaking Research at ESMO 2024
- Immunic Launches Phase 2 Trial of Vidofludimus Calcium for PCS